Tourette's syndrome has proved a tough nut to crack pharmacologically but a couple of biotechs – Sweden's Asarina Pharma and Emalex Biosciences Inc. in the US – are advancing promising candidates that could soon enter late-stage trials.
Having begun a Phase IIa study of sepranolone for the treatment of Tourette's less than a year ago, Asarina has announced that all patient examination and treatment in the trial had been completed